Principles and Practice of Urooncology

Radiotherapy, Surgery and Systemic Therapy
Springer (Verlag)
  • erschienen am 3. August 2018
  • Buch
  • |
  • Softcover
  • |
  • XVII, 445 Seiten
978-3-319-85829-6 (ISBN)
This evidence-based, state of the art guide to the management of urological malignancies, including bladder cancer, prostate cancer, and testicular cancer, is designed to serve as an easy-to-consult reference that will assist in daily decision making and the delivery of optimal care for individual patients within a multidisciplinary setting. Readers will find up-to-date information on patient selection and the full range of treatment modalities, including modern radiotherapy techniques, systemic chemotherapy, surgical procedures (including robotic surgery and other minimally invasive approaches), hormonal therapies, immunotherapy, and focal therapies. With regard to radiotherapy, the coverage encompasses everything from delineation of tumor volumes and organs at risk based on CT simulation through to delivery of stereotactic body radiotherapy, intensity-modulated radiation therapy, tomotherapy, volumetric modulated arc therapy, and proton therapy. The authors are leading authorities with international reputations who have been selected for their expertise in the topic that they address. The book will be of value for all practicing urooncologists as well as other oncology fellows and residents interested in urooncology.

Softcover reprint of the original 1st ed. 2017
  • Englisch
  • Cham
  • |
  • Schweiz
Springer International Publishing
  • Für Beruf und Forschung
  • 111 farbige Abbildungen, 120 farbige Tabellen, 44 s/w Abbildungen
  • |
  • 120 Tables, color; 111 Illustrations, color; 44 Illustrations, black and white; XVII, 445 p. 155 illus., 111 illus. in color.
  • Höhe: 23.5 cm
  • |
  • Breite: 15.5 cm
  • 948 gr
978-3-319-85829-6 (9783319858296)
weitere Ausgaben werden ermittelt

Gokhan Ozyigit graduated from Hacettepe University Faculty of Medicine (English) in 1996 and then obtained ECFMG Certification in the USA. In 2001 he completed his Residency at the Department of Radiation Oncology at Hacettepe University. He later became a Research Fellow at the Departments of Radiation Oncology at Washington University and The University of Texas M.D. Anderson Cancer Center. In 2004 he was appointed Assistant Professor at the Department of Radiation Oncology at Hacettepe University and in 2006 became an Associate Professor there. He is currently Chair at the Department of Radiation Oncology and Director of Advanced Cancer Technologies Research & Application Center at Hacettepe University. Dr. Ozyigit is an editorial board member of several international journals. He is also a reviewer or advisor for a number of other international journals, co-editor of seven previous books, and has authored numerous articles in peer-reviewed journals and book chapters. He received several national awards in the field of Oncology.He is a member of Board of Directors of Turkish Society for Radiation Oncology.

Ugur Selek graduated from Hacettepe University, Faculty of Medicine (English), in 1997, and was certified by ECFMG in USA. He completed his Radiation Oncology Residency Program in Hacettepe University in 2001. Between 2001 and 2003, he worked at University of Texas, M.D. Anderson Cancer Center, Department of Radiation Oncology, as a Clinical Fellow focusing on IMRT and Stereotactic Radiotherapy, and was awarded with "First Annual M.D. Anderson Radiation Oncology Fellow Research Award" in 2003. After his appointment as Assistant Professor in 2004, he became an Associate Professor in the Department of Radiation Oncology at Hacettepe University in 2006. Dr Selek is currently Professor of Radiation Oncology at Koc University School of Medicine, as well as being an adjunct faculty member of U.T. M.D. Anderson Cancer Center, Department of Radiation Oncology, and Chair of American Hospital-MD Anderson Radiation Treatment Center in Istanbul since 2009. Dr. Selek is a reviewer or advisor for a number of international journals, co-editor of 2 previous books, and has authored numerous articles in peer-reviewed journals and book chapters. He is a member of ASTRO International Education Subcommittee, and member of Board of Directors of both Turkish Society for Radiation Oncology and Turkish Society of Lung Cancer.

1. Selection criteria based on Radiation Oncology perspective for definitive treatment approaches in urological cancers

2. Radiological imaging in urological cancers

3. The role of functional imaging in urological cancers

4. Surgery in renal cell cancer

5. Systemic therapies in renal cell cancer

6. The role of radiotherapy in renal cell cancer

7. Screening of prostate cancer: Pros and Cons

8. Risk groupings in prostate cancer

9. Active surveillance in low risk cancer: Pros and Cons

10. Alternative focal therapies in low-risk prostate cancer: HiFU and Cryotherapy

11. Robotic surgery in prostate cancer

12. Radical retropubic prostatectomy in low-high risk prostate cancer

13. Guidelines for the delineation of primary tumor target volume in prostate cancer

14. Guidelines for the delineation of lymphatic target volumes in prostate cancer

15. Modern radiotherapy techniques in prostate cancers

16. Protontherapy for prostate cancer

17. Brachytherapy for prostate cancer

18. Stereotactic body radiotherapy for prostate cancer

19. The role of hormonal therapies and radiotherapy in prostate cancer

20. The role of hormonal therapies after surgery

21. PSA after radiotherapy: Biochemical failure and PSA bounce

22. Adjuvant and Salvage Radiotherapy in prostate cancer

23. Reirradiation in prostate cancer

24. Systemic chemotherapies in the management of prostate cancer

25. Translational research and immunotherapy in prostate cancer

26. Surgery in superficial and invasive bladder cancer

27. Target volume delineation guidelines in bladder cancer

28. Bladder preservation therapies in bladder cancer

29. Systemic chemotherapies in bladder cancers

30. Translational research and immunotherapy in bladder cancer

31. Radiolabelled targeted therapies in urological tumors

32. Radiation induced toxicity and related management strategies on urological malignancies

33. Quality assurance of modern radiotherapy techniques in urological malignancies

DNB DDC Sachgruppen

Versand in 10-15 Tagen

160,49 €
inkl. 7% MwSt.
in den Warenkorb